Blood and saliva

PreclinicalBiologic

ZZhongshan People's Hospital, Guangdong, China

Blood and saliva is one of 39 biologic programs targeting Nasopharyngeal Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

282 competitors in Nasopharyngeal Carcinoma

#DrugCompanyPhaseTrials

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

21 2

Tuoyi

SSun Yat-sen University

Phase 3

11 3

Erbitux

IImclone

Phase 3

4 4

Paraplatin

AAvyxa

Phase 3

4 5

Induction Phase1

Genmab

Phase 3

5 6

Decadron

AAspen Global Incorporated

Phase 3

1 7

Zovirax

BBp Consulting, Inc

Phase 3

1 8

Celebrex

PPhiladelphia Eye Associates

Phase 3

1 9

Gemcitabine/cisplatin

AstraZeneca

Phase 3

2 10

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Recruiting

Nasopharyngeal Carcinoma

NCT04085900

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma1 trial

Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City

Recruiting·ZZhongshan People's Hospital, Guangdong, China··NCT04085900·40,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Blood and saliva. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Blood and saliva compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Blood and saliva. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhongshan People's Hospital, Guangdong, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: ZZhongshan People's Hospital, Guangdong, China

Blood and saliva

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Nasopharyngeal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News